Innovative Medicine

Early skin and enthesitis responses in active psoriatic arthritis patients treated with TREMFYA predicted long-term clinical response, measured at two years, including disease remission Bio-naïve, TREMFYA-treated patients maintained several disease control endpoints through two years, regardless of baseline characteristics or dosing regimen

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in health-related quality of life at week 100, compared to patients without early response Additional post-hoc analyses show treatment with TREMFYA demonstrated improvements of fatigue (FACIT-F scale) at week 8, demonstrating clinically meaningful and durable long-term improvements, with nearly a third maintaining normative levels through week 100

Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action

Black Americans are up to four times more likely to have a PAD-related amputation,1 largely due to greater delays in care2 and less access to quality vascular care1 Save Legs. Change Lives.™ aims to reach more than 10 million Black Americans over the multi-year initiative

More than 50 presentations across hematologic malignancies and diseases demonstrate Janssen’s commitment to innovation and transforming the treatment of blood cancers across lines of therapy and patient types

Previously reported results from QUASAR Induction Study 1 showed clinical response was achieved by approximately 60 percent of patients at week 12 Study results presented at 2022 American College of Gastroenterology Annual Meeting showed that continued treatment with subcutaneous TREMFYA allowed a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24

55.2 percent of induction responder patients treated with STELARA at the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without corticosteroids Overall, 79.1 percent of patients treated with STELARA in the long-term extension (LTE) who were receiving corticosteroids at maintenance baseline were no longer receiving corticosteroids by week 200

Results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP) Data from a separate Phase 1 study show all three doses of investigational gene therapy JNJ-1887 met the primary endpoint for safety in adults with geographic atrophy (GA)

Talk That TalkTM encourages potentially lifesaving conversations about prostate cancer risk and importance of screening among Black men